Search

Your search keyword '"Kraxner, Helga"' showing total 25 results
Start Over Author "Kraxner, Helga" Language english
25 results on '"Kraxner, Helga"'

1. Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence–Assisted ARIA Care Pathways (ARIA 2024)

Author

Bousquet, Jean, Schünemann, Holger J., Sousa-Pinto, Bernardo, Zuberbier, Torsten, Togias, Alkis, Samolinski, Boleslaw, Bedbrook, Anna, Czarlewski, Wienczyslawa, Hofmann-Apitius, Martin, Litynska, Justyna, Vieira, Rafael José, Anto, Josep M., Fonseca, Joao A., Brozek, Jan, Bognanni, Antonio, Brussino, Luisa, Canonica, G. Walter, Cherrez-Ojeda, Ivan, Cruz, Alvaro A., Vecillas, Leticia de las, Dykewicz, Mark, Gemicioglu, Bilun, Giovannini, Mattia, Haahtela, Tari, Jacobs, Marc, Jacomelli, Cristina, Klimek, Ludger, Kvedariene, Violeta, Larenas-Linnemann, Desiree E., Louis, Gilles, Lourenço, Olga, Leemann, Lucas, Morais-Almeida, Mario, Neves, Ana Luisa, Nadeau, Kari C., Nowak, Artur, Palamarchuk, Yuliia, Palkonen, Susanna, Papadopoulos, Nikolaos G., Parmelli, Elena, Pereira, Ana Margarida, Pfaar, Oliver, Regateiro, Frederico S., Savouré, Marine, Taborda-Barata, Luis, Toppila-Salmi, Sanna K., Torres, Maria J., Valiulis, Arunas, Ventura, Maria Teresa, Williams, Sian, Yepes-Nuñez, Juan J., Yorgancioglu, Arzu, Zhang, Luo, Zuberbier, Jaron, Abdul Latiff, Amir Hamzah, Abdullah, Baharudin, Agache, Ioana, Al-Ahmad, Mona, Al-Nesf, Maryam Ali, Al Shaikh, Nada A., Amaral, Rita, Ansotegui, Ignacio J., Asllani, Julijana, Balotro-Torres, Maria Cristina, Bergmann, Karl-Christian, Bernstein, Jonathan A., Bindslev-Jensen, Carsten, Blaiss, Michael S., Bonaglia, Cristina, Bonini, Matteo, Bossé, Isabelle, Braido, Fulvio, Caballero-Fonseca, Fernan, Camargos, Paulo, Carreiro-Martins, Pedro, Casale, Thomas, Castillo-Vizuete, José-Antonio, Cecchi, Lorenzo, Teixeira, Maria do Ceu, Chang, Yoon-Seok, Loureiro, Claudia Chaves, Christoff, George, Ciprandi, Giorgio, Cirule, Ieva, Correia-de-Sousa, Jaime, Costa, Elisio M., Cvetkovski, Biljana, de Vries, Govert, Del Giacco, Stefano, Devillier, Philippe, Dokic, Dejan, Douagui, Habib, Durham, Stephen R., Enecilla, Maria Lourdes, Fiocchi, Alessandro, Fokkens, Wytske J., Fontaine, Jean-François, Gawlik, Radoslaw, Gereda, Jose E., Gil-Mata, Sara, Giuliano, Antonio F.M., Gotua, Maia, Gradauskiene, Brigita, Guzman, Maria Antonieta, Hossny, Elham, Hrubiško, Martin, Iinuma, Tomohisa, Irani, Carla, Ispayeva, Zhanat, Ivancevich, Juan Carlos, Jartti, Tuomas, Jeseňák, Miloš, Julge, Kaja, Jutel, Marek, Kaidashev, Igor, Bennoor, Kazi S., Khaltaev, Nicolai, Kirenga, Bruce, Kraxner, Helga, Kull, Inger, Kulus, Marek, Kuna, Piotr, Kupczyk, Maciej, Kurchenko, Andriy, La Grutta, Stefania, Lane, Stephen, Miculinic, Neven, Lee, Sang Min, Le Thi Tuyet, Lan, Lkhagvaa, Battur, Louis, Renaud, Mahboub, Bassam, Makela, Mika, Makris, Michael, Maurer, Marcus, Melén, Eric, Milenkovic, Branislava, Mohammad, Yousser, Moniuszko, Marcin, Montefort, Stephen, Moreira, Andre, Moreno, Pablo, Mullol, Joaquim, Nadif, Rachel, Nakonechna, Alla, Navarro-Locsin, Cecilia Gretchen, Neffen, Hugo E., Nekam, Kristof, Niedoszytko, Marek, Nunes, Elizabete, Nyembue, Dieudonné, O’Hehir, Robyn, Ollert, Markus, Ohta, Ken, Okamoto, Yoshitaka, Okubo, Kimihiro, Olze, Heidi, Padukudru, Mahesh Anand, Palomares, Oscar, Pali-Schöll, Isabella, Panzner, Petr, Palosuo, Kati, Park, Hae S., Passalacqua, Giovanni, Patella, Vincenzo, Pawankar, Ruby, Pétré, Benoît, Pitsios, Constantinos, Plavec, Davor, Popov, Todor A., Puggioni, Francesca, Quirce, Santiago, Raciborski, Filip, Ramonaité, Agné, Recto, Marysia, Repka-Ramirez, Susana, Roberts, Graham, Robles-Velasco, Karla, Roche, Nicolas, Rodriguez-Gonzalez, Monica, Romualdez, Joel A., Rottem, Menachem, Rouadi, Philip W., Salapatas, Marianella, Sastre, Joaquin, Serpa, Faradiba S., Sayah, Zineb, Scichilone, Nicola, Senna, Gianenrico, Sisul, Juan Carlos, Solé, Dirceu, Soto-Martinez, Manuel E., Sova, Milan, Sozinova, Olga, Stevanovic, Katarina, Ulrik, Charlotte Suppli, Szylling, Anna, Tan, Frances M., Tantilipikorn, Pongsakorn, Todo-Bom, Ana, Tomic-Spiric, Vesna, Tsaryk, Vladyslav, Tsiligianni, Ioanna, Urrutia-Pereira, Marilyn, Rostan, Marylin Valentin, Sofiev, Mikhail, Valovirta, Erkka, Van Eerd, Michiel, Van Ganse, Eric, Vasankari, Tuula, Vichyanond, Pakit, Viegi, Giovanni, Wallace, Dana, Wang, De Yun, Waserman, Susan, Wong, Gary, Worm, Margitta, Yusuf, Osman M., Zaitoun, Fares, and Zidarn, Mihaela

Published
2024
Full Text
View/download PDF

2. MASK-air: An OECD (Organisation for Economic Co-operation and Development) Best Practice for Public Health on Integrated Care for Chronic Diseases

Author

Czarlewski, Wienczyslawa, Haahtela, Tari, Canonica, G. Walter, Costa, Elisio M., Klimek, Ludger, Kuna, Piotr, Kupczyk, Maciej, Kvedariene, Violeta, Kulus, Marek, Larenas-Linnemann, Désirée E., Louis, Renaud, Pfaar, Oliver, Papadopoulos, Nikolaos G., Pham-Thi, Nhân, Regateiro, Frederico S., Roche, Nicolas, Samolinski, Boleslaw, Sastre, Joaquin, Scichilone, Nicola, Taborda-Barata, Luis, Valiulis, Arunas, Yorgancioglu, Arzu, Ventura, Maria Teresa, Almeida, Rute, Amaral, Rita, Ansotegui, Ignacio J., Bergmann, Karl C., Bosnic-Anticevich, Sinthia, Braido, Fulvio, Brussino, Luisa, Cardona, Victoria, Cecchi, Lorenzo, Loureiro, Claudia Chaves, Cingi, Cemal, Cruz, Alvaro A., Fokkens, Wytske J., de Vries, Govert, Gemicioglu, Bilun, Giuliano, Antonio F.M., Linuma, Tomohisa, Ivancevich, Juan Carlos, Jácome, Cristina, Kaidashev, Igor, Kraxner, Helga, Laune, Daniel, Louis, Gilles, Lourenço, Olga, Makela, Mika, Makris, Michael, Morais-Almeida, Mario, Mösges, Ralph, Maurer, Marcus, Mullol, Joaquim, Nadif, Rachel, Niedoszytko, Marek, O’Hehir, Robyn, Okamoto, Yoshitaka, Ollert, Markus, Olze, Heidi, Patella, Vincenzo, Pétré, Benoit, Puggioni, Francesca, Romantowski, Jan, Rouadi, Philip W., Reitsma, Sietze, Rivero-Yeverino, Daniela, Rodriguez-Gonzalez, Monica, Sá-Sousa, Ana, Savouré, Marine, Serpa, Faradiba S., Shamji, Mohamed H., Sheikh, Aziz, Ulrik, Charlotte Suppli, Sofiev, Mikhail, Sova, Milan, Sperl, Annette, Todo-Bom, Ana, Tomazic, Peter V., Toppila-Salmi, Sanna, Tsiligianni, Ioanna, Valovirta, Erkka, van Eerd, Michiel, Zidarn, Mihaela, Blain, Hubert, Boulet, Louis-Philippe, Brusselle, Guy, Buhl, Roland, Charpin, Denis, Casale, Thomas, Chivato, Tomas, Correia-de-Sousa, Jaime, Corrigan, Christopher, de Blay, Frédéric, Del Giacco, Stefano, Devillier, Philippe, Dykewicz, Mark, Fiocchi, Alessandro, Giovannini, Mattia, Jassem, Ewa, Jutel, Marek, Keil, Thomas, La Grutta, Stefania, Lipworth, Brian, Papi, Alberto, Pépin, Jean-Louis, Quirce, Santiago, Cordeiro, Carlos Robalo, Torres, Maria J., Usmani, Omar S., Bousquet, Jean, Sousa-Pinto, Bernardo, Anto, Josep M., Bedbrook, Anna, Fonseca, Joao A., and Zuberbier, Torsten

Published
2024
Full Text
View/download PDF

3. Poor Rhinitis and Asthma Control Is Associated With Decreased Health-Related Quality of Life and Utilities: A MASK-air Study

Author

Czarlewski, Wienczyslawa, Bedbrook, Anna, Haahtela, Tari, Canonica, G. Walter, Costa, Elisio M., Kupczyk, Maciej, Kvedariene, Violeta, Kulus, Marek, Larenas-Linnemann, Désirée E., Pfaar, Oliver, Papadopoulos, Nikolaos G., Pham-Thi, Nhân, Regateiro, Frederico S., Roche, Nicolas, Sastre, Joaquin, Scichilone, Nicola, Taborda-Barata, Luis, Valiulis, Arunas, Yorgancioglu, Arzu, Ventura, Maria Teresa, Almeida, Rute, Amaral, Rita, Ansotegui, Ignacio J., Bergmann, Karl C., Bosnic-Anticevich, Sinthia, Braido, Fulvio, Brussino, Luisa, Cardona, Victoria, Cecchi, Lorenzo, Loureiro, Claudia Chaves, Cingi, Cemal, Cruz, Alvaro A., Fokkens, Wytske J., de Vries, Govert, Gemicioglu, Bilun, Giuliana, Antonio F.M., Linuma, Tomohisa, Ivancevich, Juan Carlos, Jácome, Cristina, Kaidashev, Igor, Kraxner, Helga, Laune, Daniel, Louis, Gilles, Lourenço, Olga, Makela, Mika, Makris, Michael, Mösges, Ralph, Maurer, Marcus, Mullol, Joaquim, Nadif, Rachel, Niedoszytko, Marek, O’Hehir, Robyn, Okamoto, Yoshitaka, Ollert, Markus, Olze, Heidi, Patella, Vincenzo, Pétré, Benoit, Puggioni, Francesca, Romantowski, Jan, Rouadi, Philip W., Reitsma, Sietze, Rivero-Yeverino, Daniela, Rodriguez-Gonzalez, Monica, Sá-Sousa, Ana, Serpa, Faradiba S., Shamji, Mohamed H., Sheikh, Aziz, Ulrik, Charlotte Suppli, Sofiev, Mikhail, Sova, Milan, Sperl, Annette, Todo-Bom, Ana, Tomazic, Peter V., Toppila-Salmi, Sanna, Tsiligianni, Ioanna, Valovirta, Erkka, van Eerd, Michiel, Zidarn, Mihaela, Blain, Hubert, Boulet, Louis-Philippe, Brusselle, Guy, Buhl, Roland, Charpin, Denis, Casale, Thomas, Chivato, Tomas, Correia-de-Sousa, Jaime, Corrigan, Christopher, de Blay, Frédéric, Del Giacco, Stefano, Devillier, Philippe, Dykewicz, Mark, Fiocchi, Alessandro, Giovannini, Mattia, Jassem, Ewa, Jutel, Marek, Keil, Thomas, La Grutta, Stefania, Lipworth, Brian, Papi, Alberto, Pépin, Jean-Louis, Quirce, Santiago, Cordeiro, Carlos Robalo, Torres, Maria J., Usmani, Omar S., Vieira, Rafael José, Leemann, Lucas, Briggs, Andrew, Pereira, Ana Margarida, Savouré, Marine, Kuna, Piotr, Morais-Almeida, Mário, Bewick, Michael, Azevedo, Luís Filipe, Louis, Renaud, Klimek, Ludger, Bahbah, Farah, Samolinski, Boleslaw, Anto, Josep M., Zuberbier, Torsten, Fonseca, João A., Bousquet, Jean, and Sousa-Pinto, Bernardo

Published
2024
Full Text
View/download PDF

4. Impairment of EQ-5D-5L Domains According to Allergic Rhinitis and Asthma Control: A MASK-air Real-World Study

Author

Sousa-Pinto, Bernardo, Louis, Gilles, Rodrigues, Jorge, Giuliano, Antonio Francesco Maria, Baiardini, Ilaria, Braido, Fulvio, Czarlewski, Wienczyslawa, Bedbrook, Anna, Haahtela, Tari, Valiulis, Arunas, Brussino, Luisa, Cecchi, Lorenzo, Cruz, Alvaro A., Gemicioglu, Bilun, Fokkens, Wytske J., Ivancevich, Juan Carlos, Klimek, Ludger, Kraxner, Helga, Kuna, Piotr, Kupczyk, Maciej, Kvedariene, Violeta, Larenas-Linnemann, Désirée, Louis, Renaud, Nadif, Rachel, Niedoszytko, Marek, Okamoto, Yoshitaka, Ollert, Markus, Papadopoulos, Nikolaos G., Patella, Vincenzo, Pawankar, Ruby, Pham-Thi, Nhân, Pfaar, Oliver, Regateiro, Frederico S., Roche, Nicolas, Rouadi, Philip W., Samolinski, Boleslaw, Sastre, Joaquin, Savouré, Marine, Scichilone, Nicola, Sheikh, Aziz, Taborda-Barata, Luís, Toppila-Salmi, Sanna, Yorgancioglu, Arzu, Zidarn, Mihaela, Anto, Josep M., Zuberbier, Torsten, Canonica, G. Walter, Ventura, Maria Teresa, Fonseca, João A., Pétré, Benoit, and Bousquet, Jean

Published
2023
Full Text
View/download PDF

5. Cutoff Values of MASK-air Patient-Reported Outcome Measures

Author

Sousa-Pinto, Bernardo, Sá-Sousa, Ana, Vieira, Rafael José, Amaral, Rita, Pereira, Ana Margarida, Anto, Josep M., Klimek, Ludger, Czarlewski, Wienczyslawa, Mullol, Joaquim, Pfaar, Oliver, Bedbrook, Anna, Brussino, Luisa, Kvedariene, Violeta, Larenas-Linnemann, Desirée E., Okamoto, Yoshitaka, Ventura, Maria Teresa, Ansotegui, Ignacio J., Bosnic-Anticevich, Sinthia, Canonica, G. Walter, Cardona, Victoria, Cecchi, Lorenzo, Chivato, Tomas, Cingi, Cemal, Costa, Elísio M., Cruz, Alvaro A., Del Giacco, Stefano, Devillier, Philippe, Fokkens, Wytske J., Gemicioglu, Bilun, Haahtela, Tari, Ivancevich, Juan Carlos, Kuna, Piotr, Kaidashev, Igor, Kraxner, Helga, Laune, Daniel, Louis, Renaud, Makris, Michael, Monti, Riccardo, Morais-Almeida, Mario, Mösges, Ralph, Niedoszytko, Marek, Papadopoulos, Nikolaos G., Patella, Vincenzo, Pham-Thi, Nhân, Regateiro, Frederico S., Reitsma, Sietze, Rouadi, Philip W., Samolinski, Boleslaw, Sheikh, Aziz, Sova, Milan, Taborda-Barata, Luis, Toppila-Salmi, Sanna, Sastre, Joaquin, Tsiligianni, Ioanna, Valiulis, Arunas, Yorgancioglu, Arzu, Zidarn, Mihaela, Zuberbier, Torsten, Fonseca, Joao A., and Bousquet, Jean

Published
2023
Full Text
View/download PDF

6. Consistent trajectories of rhinitis control and treatment in 16,177 weeks

Author

Sousa-Pinto, Bernardo, Schünemann, Holger J., Sá-Sousa, Ana, Vieira, Rafael José, Amaral, Rita, Anto, Josep M., Klimek, Ludger, Czarlewski, Wienczyslawa, Mullol, Joaquim, Pfaar, Oliver, Bedbrook, Anna, Brussino, Luisa, Kvedariene, Violeta, Larenas-Linnemann, Désirée E., Okamoto, Yoshitaka, Ventura, Maria Teresa, Agache, Ioana, Ansotegui, Ignacio J., Bergmann, Karl C., Bosnic-Anticevich, Sinthia, Canonica, G. Walter, Cardona, Victoria, Carreiro-Martins, Pedro, Casale, Thomas, Cecchi, Lorenzo, Chivato, Tomas, Chu, Derek K., Cingi, Cemal, Costa, Elísio M., Cruz, Alvaro A., Del Giacco, Stefano, Devillier, Philippe, Eklund, Patrik, Fokkens, Wytske J., Gemicioglu, Bilun, Haahtela, Tari, Ivancevich, Juan Carlos, Ispayeva, Zhanat, Jutel, Marek, Kuna, Piotr, Kaidashev, Igor, Khaitov, Musa, Kraxner, Helga, Laune, Daniel, Lipworth, Brian, Louis, Renaud, Makris, Michael, Monti, Riccardo, Morais-Almeida, Mario, Mösges, Ralph, Niedoszytko, Marek, Papadopoulos, Nikolaos G., Patella, Vincenzo, Pham-Thi, Nhân, Regateiro, Frederico S., Reitsma, Sietze, Rouadi, Philip W., Samolinski, Boleslaw, Sheikh, Aziz, Sova, Milan, Todo-Bom, Ana, Taborda-Barata, Luis, Toppila-Salmi, Sanna, Sastre, Joaquin, Tsiligianni, Ioanna, Valiulis, Arunas, Vandenplas, Olivier, Wallace, Dana, Waserman, Susan, Yorgancioglu, Arzu, Zidarn, Mihaela, Zuberbier, Torsten, Fonseca, Joao A., Bousquet, Jean, and NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)

Subjects
rhinitis, real-world data, patient-reported outcomes, Immunology, Immunology and Allergy, mobile health
Abstract

Funding Information: MASK‐air® has been supported by EU grants (POLLAR, EIT Health; Structural and Development Funds, Twinning, EIP on AHA and H2020) and educational grants from Mylan‐Viatris, ALK, GSK, Novartis and Uriach. Publisher Copyright: © 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. Introduction: Data from mHealth apps can provide valuable information on rhinitis control and treatment patterns. However, in MASK-air®, these data have only been analyzed cross-sectionally, without considering the changes of symptoms over time. We analyzed data from MASK-air® longitudinally, clustering weeks according to reported rhinitis symptoms. Methods: We analyzed MASK-air® data, assessing the weeks for which patients had answered a rhinitis daily questionnaire on all 7 days. We firstly used k-means clustering algorithms for longitudinal data to define clusters of weeks according to the trajectories of reported daily rhinitis symptoms. Clustering was applied separately for weeks when medication was reported or not. We compared obtained clusters on symptoms and rhinitis medication patterns. We then used the latent class mixture model to assess the robustness of results. Results: We analyzed 113,239 days (16,177 complete weeks) from 2590 patients (mean age ± SD = 39.1 ± 13.7 years). The first clustering algorithm identified ten clusters among weeks with medication use: seven with low variability in rhinitis control during the week and three with highly-variable control. Clusters with poorly-controlled rhinitis displayed a higher frequency of rhinitis co-medication, a more frequent change of medication schemes and more pronounced seasonal patterns. Six clusters were identified in weeks when no rhinitis medication was used, displaying similar control patterns. The second clustering method provided similar results. Moreover, patients displayed consistent levels of rhinitis control, reporting several weeks with similar levels of control. Conclusions: We identified 16 patterns of weekly rhinitis control. Co-medication and medication change schemes were common in uncontrolled weeks, reinforcing the hypothesis that patients treat themselves according to their symptoms. publishersversion published

Published
2023

7. The ARIA-MASK-air® approach

Author

Bousquet, Jean, Anto, Josep M., Sousa-Pinto, Bernardo, Czarlewski, Wienczyslawa, Bedbrook, Anna, Haahtela, Tari, Klimek, Ludger, Pfaar, Oliver, Kuna, Piotr, Kupczyk, Maciej, Regateiro, Frederico S., Samolinski, Boleslaw, Valiulis, Arunas, Yorgancioglu, Arzu, Arnavielhe, Sylvie, Basagaña, Xavier, Bergmann, Karl C., Bosnic-Anticevich, Sinthia, Brussino, Luisa, Canonica, G. Walter, Cardona, Victoria, Cecchi, Lorenzo, Chaves-Loureiro, Claudia, Costa, Elisio, Cruz, Alvaro A., Gemicioglu, Bilun, Fokkens, Wytske J., Ivancevich, Juan Carlos, Kraxner, Helga, Kvedariene, Violeta, Larenas-Linnemann, Désirée E., Laune, Daniel, Louis, Renaud, Makris, Michael, Maurer, Marcus, Melén, Erik, Micheli, Yann, Morais-Almeida, Mario, Mullol, Joaquim, Niedoszytko, Marek, Okamoto, Yoshitaka, Papadopoulos, Nikolaos G., Patella, Vincenzo, Pham-Thi, Nhân, Rouadi, Philip W., Sastre, Joaquin, Scichilone, Nicola, Sheikh, Aziz, Sofiev, Mikhail, Taborda-Barata, Luis, Toppila-Salmi, Sanna, Tsiligianni, Ioanna, Valovirta, Erkka, Ventura, Maria Teresa, Vieira, Rafael José, Zidarn, Mihaela, Amaral, Rita, Ansotegui, Ignacio J., Bédard, Annabelle, Benveniste, Samuel, Bewick, Michael, Bindslev-Jensen, Carsten, Blain, Hubert, Bonini, Matteo, Bourret, Rodolphe, Braido, Fulvio, Carreiro-Martins, Pedro, Charpin, Denis, Cherrez-Ojeda, Ivan, Chivato, Tomas, Chu, Derek K., Cingi, Cemal, Del Giacco, Stefano, de Blay, Frédéric, Devillier, Philippe, De Vries, Govert, Doulaptsi, Maria, Doyen, Virginie, Dray, Gérard, Fontaine, Jean François, Gomez, R. Maximiliano, Hagemann, Jan, Heffler, Enrico, Hofmann, Maja, Jassem, Ewa, Jutel, Marek, Keil, Thomas, Kritikos, Vicky, Kull, Inger, Kulus, Marek, Lourenço, Olga, Mathieu-Dupas, Eve, Menditto, Enrica, Mösges, Ralph, Murray, Ruth, Nadif, Rachel, Neffen, Hugo, Nicola, Stefania, O’Hehir, Robyn, Olze, Heidi, Palamarchuk, Yuliia, Pépin, Jean Louis, Pétré, Benoit, Picard, Robert, Pitsios, Constantinos, Puggioni, Francesca, Quirce, Santiago, Raciborski, Filip, Reitsma, Sietze, Roche, Nicolas, Rodriguez-Gonzalez, Monica, Romantowski, Jan, Sá-Sousa, Ana, Serpa, Faradiba S., Savouré, Marine, Shamji, Mohamed H., Sova, Milan, Sperl, Annette, Stellato, Cristiana, Todo-Bom, Ana, Tomazic, Peter Valentin, Vandenplas, Olivier, Van Eerd, Michiel, Vasankari, Tuula, Viart, Frédéric, Waserman, Susan, Fonseca, Joao A., Zuberbier, Torsten, NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM), and Comprehensive Health Research Centre (CHRC) - pólo NMS

Subjects
Pulmonary and Respiratory Medicine, rhinitis, mHealth, digital, Immunology, Immunology and Allergy, asthma, MASK-air
Abstract

Funding Information: The authors thank Ms Véronique Pretschner for submitting the paper. MASK‐air has been supported by Charité Universitätsmedizin Berlin, EU grants (EU Structural and Development Funds Languedoc Roussillon and Region PACA; POLLAR: EIT Health; Twinning: EIP on AHA; Twinning DHE: H2020; Catalyse: Horizon Europe) and educational grants from Mylan‐Viatris, ALK, GSK, Novartis, Stallergènes‐Greer and Uriach. None for the study. ® Publisher Copyright: © 2023 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology. MASK-air®, a validated mHealth app (Medical Device regulation Class IIa) has enabled large observational implementation studies in over 58,000 people with allergic rhinitis and/or asthma. It can help to address unmet patient needs in rhinitis and asthma care. MASK-air® is a Good Practice of DG Santé on digitally-enabled, patient-centred care. It is also a candidate Good Practice of OECD (Organisation for Economic Co-operation and Development). MASK-air® data has enabled novel phenotype discovery and characterisation, as well as novel insights into the management of allergic rhinitis. MASK-air® data show that most rhinitis patients (i) are not adherent and do not follow guidelines, (ii) use as-needed treatment, (iii) do not take medication when they are well, (iv) increase their treatment based on symptoms and (v) do not use the recommended treatment. The data also show that control (symptoms, work productivity, educational performance) is not always improved by medications. A combined symptom-medication score (ARIA-EAACI-CSMS) has been validated for clinical practice and trials. The implications of the novel MASK-air® results should lead to change management in rhinitis and asthma. publishersversion published

Published
2023

8. A study using MASK-air® real-world data

Author

Sousa-Pinto, Bernardo, Sá-Sousa, Ana, Vieira, Rafael José, Amaral, Rita, Klimek, Ludger, Czarlewski, Wienczyslawa, Antó, Josep M, Pfaar, Oliver, Bedbrook, Anna, Kvedariene, Violeta, Ventura, Maria Teresa, Ansotegui, Ignacio J, Bergmann, Karl-Christian, Brussino, Luisa, Canonica, G Walter, Cardona, Victoria, Carreiro-Martins, Pedro, Casale, Tomas, Cecchi, Lorenzo, Chivato, Tomás, Chu, Derek K, Cingi, Cemal, Costa, Elísio M, Cruz, Alvaro A, De Feo, Giulia, Devillier, Philippe, Fokkens, Wytske J, Gaga, Mina, Gemicioğlu, Bilun, Haahtela, Tari, Ivancevich, Juan Carlos, Ispayeva, Zhanat, Jutel, Marek, Kuna, Piotr, Kaidashev, Igor, Kraxner, Helga, Larenas-Linnemann, Désirée E, Laune, Daniel, Lipworth, Brian, Louis, Renaud, Makris, Michael, Monti, Ricardo, Morais-Almeida, Mario, Mösges, Ralph, Mullol, Joaquim, Odemyr, Mikaëla, Okamoto, Yoshitaka, Papadopoulos, Nikolaos G, Patella, Vincenzo, Pham-Thi, Nhân, Regateiro, Frederico S, Reitsma, Sietze, Rouadi, Philip W, Samolinski, Boleslaw, Sova, Milan, Todo-Bom, Ana, Taborda-Barata, Luis, Tomazic, Peter Valentin, Toppila-Salmi, Sanna, Sastre, Joaquin, Tsiligianni, Ioanna, Valiulis, Arunas, Vandenplas, Olivier, Wallace, Dana, Waserman, Susan, Yorgancioglu, Arzu, Zidarn, Mihaela, Zuberbier, Torsten, Fonseca, João Almeida, Bousquet, Jean, NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM), Centro de Estudos de Doenças Crónicas (CEDOC), and Comprehensive Health Research Centre (CHRC) - pólo NMS

Abstract

Funding: This study was funded by ARIA. MASK-air® has been supported by EU grants (EU Structural and Development grant, POLLAR: EIT Health and Structural and Development Funds) and educational grants from Mylan-Viatris, ALK, GSK, Novartis and Uriach. Open Access funding enabled and organized by Projekt DEAL. BACKGROUND: Co-medication is common among patients with allergic rhinitis (AR), but its dimension and patterns are unknown. This is particularly relevant since AR is understood differently across European countries, as reflected by rhinitis-related search patterns in Google Trends. This study aims to assess AR co-medication and its regional patterns in Europe, using real-world data. METHODS: We analysed 2015-2020 MASK-air® European data. We compared days under no medication, monotherapy, and co-medication using the visual analogue scale (VAS) levels for overall allergic symptoms ("VAS Global Symptoms") and impact of AR on work. We assessed the monthly use of different medication schemes, performing separate analyses by region (defined geographically or by Google Trends patterns). We estimated the average number of different drugs reported per patient within one year. RESULTS: We analysed 222,024 days (13,122 users), including 63,887 days (28.8%) under monotherapy, and 38,315 (17.3%) under co-medication. The median "VAS Global Symptoms" was 7 for no medication days, 14 for monotherapy and 21 for co-medication (p

Published
2022

9. Results of a Bayesian mixed-effects model

Author

Sousa-Pinto, Bernardo, Azevedo, Luís Filipe, Sá-Sousa, Ana, Vieira, Rafael José, Amaral, Rita, Klimek, Ludger, Czarlewski, Wienczyslawa, Anto, Josep M., Bedbrook, Anna, Kvedariene, Violeta, Ventura, Maria Teresa, Ansotegui, Ignacio J., Bergmann, Karl Christian, Brussino, Luisa, Canonica, G. Walter, Cardona, Victoria, Carreiro-Martins, Pedro, Casale, Thomas, Cecchi, Lorenzo, Chivato, Tomás, Chu, Derek K., Cingi, Cemal, Costa, Elisio M., Cruz, Alvaro A., De Feo, Giulia, Devillier, Philippe, Fokkens, Wytske J., Gaga, Mina, Gemicioğlu, Bilun, Haahtela, Tari, Ivancevich, Juan Carlos, Ispayeva, Zhanat, Jutel, Marek, Kuna, Piotr, Kaidashev, Igor, Kraxner, Helga, Larenas-Linnemann, Désirée E., Laune, Daniel, Lipworth, Brian, Louis, Renaud, Makris, Michaël, Monti, Riccardo, Morais-Almeida, Mario, Mösges, Ralph, Mullol, Joaquim, Odemyr, Mikaëla, Okamoto, Yoshitaka, Papadopoulos, Nikolaos G., Patella, Vincenzo, Pham-Thi, Nhân, Regateiro, Frederico S., Reitsma, Sietze, Rouadi, Philip W., Samolinski, Boleslaw, Sova, Milan, Todo-Bom, Ana, Taborda-Barata, Luis, Tomazic, Peter Valentin, Toppila-Salmi, Sanna, Sastre, Joaquin, Tsiligianni, Ioanna, Valiulis, Arunas, Wallace, Dana, Waserman, Susan, Yorgancioglu, Arzu, Zidarn, Mihaela, Zuberbier, Torsten, Fonseca, João Almeida, Bousquet, Jean, Pfaar, Oliver, NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM), and Comprehensive Health Research Centre (CHRC) - pólo NMS

Subjects
Pulmonary and Respiratory Medicine, allergic rhinitis, patient-reported outcomes, Immunology, Immunology and Allergy, real-life data analysis, immunotherapy, mobile health
Abstract

Funding Information: MASK-air has been supported by Charit? Universit?tsmedizin Berlin, EU Grants (EU Structural and Development Funds, POLLAR: EIT Health POLLAR, EIT Health Twinning) and educational grants from Mylan-Viatris, ALK, GSK, Novartis and Uriach. Open access funding enabled and organized by Projekt DEAL. Publisher Copyright: © 2022 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology. Background: Evidence regarding the effectiveness of allergen immunotherapy (AIT) on allergic rhinitis has been provided mostly by randomised controlled trials, with little data from real-life studies. Objective: To compare the reported control of allergic rhinitis symptoms in three groups of users of the MASK-air® app: those receiving sublingual AIT (SLIT), those receiving subcutaneous AIT (SCIT), and those receiving no AIT. Methods: We assessed the MASK-air® data of European users with self-reported grass pollen allergy, comparing the data reported by patients receiving SLIT, SCIT and no AIT. Outcome variables included the daily impact of allergy symptoms globally and on work (measured by visual analogue scales—VASs), and a combined symptom-medication score (CSMS). We applied Bayesian mixed-effects models, with clustering by patient, country and pollen season. Results: We analysed a total of 42,756 days from 1,093 grass allergy patients, including 18,479 days of users under AIT. Compared to no AIT, SCIT was associated with similar VAS levels and CSMS. Compared to no AIT, SLIT-tablet was associated with lower values of VAS global allergy symptoms (average difference = 7.5 units out of 100; 95% credible interval [95%CrI] = −12.1;−2.8), lower VAS Work (average difference = 5.0; 95%CrI = −8.5;−1.5), and a lower CSMS (average difference = 3.7; 95%CrI = −9.3;2.2). When compared to SCIT, SLIT-tablet was associated with lower VAS global allergy symptoms (average difference = 10.2; 95%CrI = −17.2;−2.8), lower VAS Work (average difference = 7.8; 95%CrI = −15.1;0.2), and a lower CSMS (average difference = 9.3; 95%CrI = −18.5;0.2). Conclusion: In patients with grass pollen allergy, SLIT-tablet, when compared to no AIT and to SCIT, is associated with lower reported symptom severity. Future longitudinal studies following internationally-harmonised standards for performing and reporting real-world data in AIT are needed to better understand its ‘real-world’ effectiveness. publishersversion published

Published
2022

10. The Correlation between the Results of the Sniffin' Sticks Test, Demographic Data, and Questionnaire of Olfactory Disorders in a Hungarian Population after a SARS-CoV-2 Infection.

Author

Molnár, András, Maihoub, Stefani, Mavrogeni, Panayiota, Krasznai, Magdolna, Tamás, László, and Kraxner, Helga

Subjects
SMELL disorders, SARS-CoV-2, COVID-19
Abstract

Background: After a severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, smell disorders frequently occur, significantly affecting patients' quality of life (QoL). Methods: 110 patients with persistent olfactory disorder after coronavirus infection were enrolled. These patients underwent chemosensory testing using the Sniffin' Sticks test, and completed the Questionnaire of Olfactory Disorders (QOD). Results: 30% of the patients reported anosmia, and 70% reported hyposmia. Upon comparing subjective and chemosensory testing categories, good category matching was observed in 75.3% (i.e., anosmia based on both methods in 10 and hyposmia in 48 cases). Statistical analysis using the Chi-square test revealed a significant result (p = 0.001 *). Between the TDI (i.e., Threshold, Discrimination, Identification) results of the three subjective report groups (i.e., hyposmia, anosmia, and parosmia), no significant differences were observed. When the TDI and QOD results were compared, no consistent significant correlations were found in most TDI and QOD outcomes. Between the TDI and Scale 2 results, a significant, although slight correlation was observed by the Spearman's (rho = 0.213, p = 0.027 *) and Pearson's (rho = 0.201, p = 0.037 *) tests. Conclusions: The nonsignificant correlation between objective and subjective methods suggests that these results should be interpreted independently. Moreover, adequate management is essential even in mild cases. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

11. ARIA‐EAACI care pathways for allergen immunotherapy in respiratory allergy

Author

Bousquet, Jean, Pfaar, Oliver, Agache, Ioana, Bedbrook, Anna, Akdis, Cezmi A, Canonica, Giorgio Walter, Chivato, Tomas, Al-Ahmad, Mona, Rasib, A. H. Abdul, Ansotegui, Ignacio J, Bachert, Claus, Soto-Martinez, Manuel, Laune, Daniel, Casale, Tomas, Levin, Michael, Larenas-Linnemann, Désirée, Samolinski, Boleslaw, Lodrup Carlsen, Karin C, O'Mahony, Liam, Lombardi, Carlo, Riggioni, Carmen, Hossny, Elham, Barata, Luís Taborda, Lourenço, Olga, Devillier, Philippe, Mahboub, Bassam, Malling, Hans-Jørgen, Sheikh, Aziz, Manning, Patrick, Passalacqua, Giovanni, Marshall, Gailen D, Sanchez-Borges, Mario, Toppila-Salmi, Sanna, Melén, Erik, Fokkens, Wytske J, Meltzer, Eli O, Miculinic, Neven, Soto-Quiros, Manuel, Milenkovic, Branislava, Roberts, Graham, Ohta, Ken, Scichilone, Nicola, Moin, Mostafa, Odemyr, Mikaëla, Montefort, Stephen, Almeida, Mário Morais, Bom, Ana Todo, Mortz, Charlotte G, Serpa, Faradiba S, Patella, Vincenzo, Sova, Milan, Mösges, Ralph, Mullol, Joaquim, Namazova Baranova, Leyla, Tsiligianni, Ioanna, Neffen, Hugo, Bjermer, Leif, Rodriguez-Gonzales, Monica, Torres, Maria J, Okamoto, Yoshitaka, Okubo, Kimi, Pajno, Giovanni B, Baharuddin, Abdullah, Cecchi, Lorenzo, Sastre, Joaquin, Untersmayr, Eva, Pawankar, Ruby, Pham-Thi, Nhân, Plavec, Davor, Cardona, Victoria, Dokic, Dejan, Sisul, Juan Carlos, Rosario, Nelson, Rottem, Menachem, Rouadi, Philip W, Del Giacco, Stefano, Fonseca, Joao A, Schwarze, Jürgen, Scadding, Glenis K, Shamji, Mohamed H, Schmid-Grendelmeier, Peter, Niedoszytko, Marek, Valentin-Rostan, Marylin, Sofiev, Mikhail, Solé, Dirceu, Sooronbaev, Talant, Palkonen, Susanna, Urrutia-Pereira, Marilyn, Skypala, Isabel, Suppli-Ulrik, Charlotte, Bonini, Matteo, Popov, Todor A, Tomazic, Peter-Valentin, Valero, Antonio, Cepeda Sarabia, Alfonso M, Ryan, Dermot, Bosnic-Anticevich, Sinthia, Valiulis, Arunas, Durham, Stephen L, Schünemann, Holger, Kalayci, Omer, Valovirta, Erkka, Panzner, Petr, Vandenplas, Olivier, Ventura, Maria Teresa, Gotua, Maia, Vichyanond, Pakit, Chkhartishvili, Ekaterine, Wagenmann, Martin, Fontaine, Jean-François, Kull, Inger, Wallace, Dana, Recto, Marysia, Walusiak-Skorupa, Jolanta, Wang, De Yun, Hrubiško, Martin, Waserman, Susan, Ebisawa, Motohiro, Bosse, Isabelle, Grisle, Ineta, Wong, Gary Wk, Bindslev-Jensen, Carsten, Yorgancioglu, Arzu, Yusuf, Osman M, Khaitov, Musa, Zernotti, Mario, Gawlik, Radoslaw, Chu, Derek K, Irani, Carla, Zhang, Luo, Zidarn, Mihaela, Zuberbier, Torsten, Kuna, Piotr, Jutel, Marek, Guzmán, Maria Antonieta, El-Gamal, Yehia, Klimek, Ludger, Brough, Helen A, Brussino, Luisa, Calderon, Moises A, Caraballo, Luis, O'Hehir, Robyn E, Gelincik, Asli, Kvedariene, Violeta, Cirule, Ieva, Cruz, Alvaro A, Czarlewski, Wienczyslawa, Nekam, Kristof, Papadopoulos, Nikolaos G., Haahtela, Tari, Emuzyte, Regina, Gamkrelidze, Amiran, Fauquert, Jean Luc, Palomares, Oscar, Regateiro, Frederico S, Ivancevich, Juan Carlos, Gemicioglu, Bilun, Gereda, Jose E, Gerth van Wijk, Roy, Bergmann, Karl-Christian, Knol, Edward, Halken, Susanne, Heffler, Enrico, Hoffmann-Sommergruber, Karin, Martins, Pedro Carreiro, Kritikos, Vicky, Ispayeva, Zhanat, Julge, Kaja, Kaidashev, Igor, Demoly, Pascal, Kowalski, Marek, Kraxner, Helga, Ollert, Markus, Fiocchi, Alessandro, Lauerma, Antti, Lau, Susanne, Park, Hae-Sim, Gomez, R Maximiliano, Comprehensive Health Research Centre (CHRC) - pólo NMS, Centro de Estudos de Doenças Crónicas (CEDOC), NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM), uBibliorum, Bousquet J., Pfaar O., Agache I., Bedbrook A., Akdis C.A., Canonica G.W., Chivato T., Al-Ahmad M., Abdul Latiff A.H., Ansotegui I.J., Bachert C., Baharuddin A., Bergmann K.-C., Bindslev-Jensen C., Bjermer L., Bonini M., Bosnic-Anticevich S., Bosse I., Brough H.A., Brussino L., Calderon M.A., Caraballo L., Cardona V., Carreiro-Martins P., Casale T., Cecchi L., Cepeda Sarabia A.M., Chkhartishvili E., Chu D.K., Cirule I., Cruz A.A., Czarlewski W., del Giacco S., Demoly P., Devillier P., Dokic D., Durham S.L., Ebisawa M., El-Gamal✝ Y., Emuzyte R., Gamkrelidze A., Fauquert J.L., Fiocchi A., Fokkens W.J., Fonseca J.A., Fontaine J.-F., Gawlik R., Gelincik A., Gemicioglu B., Gereda J.E., Gerth van Wijk R., Gomez R.M., Gotua M., Grisle I., Guzman M.-A., Haahtela T., Halken S., Heffler E., Hoffmann-Sommergruber K., Hossny E., Hrubisko M., Irani C., Ivancevich J.C., Ispayeva Z., Julge K., Kaidashev I., Kalayci O., Khaitov M., Klimek L., Knol E., Kowalski M.L., Kraxner H., Kull I., Kuna P., Kvedariene V., Kritikos V., Lauerma A., Lau S., Laune D., Levin M., Larenas-Linnemann D.E., Lodrup Carlsen K.C., Lombardi C., Lourenco O.M., Mahboub B., Malling H.-J., Manning P., Marshall G.D., Melen E., Meltzer E.O., Miculinic N., Milenkovic B., Moin M., Montefort S., Morais-Almeida M., Mortz C.G., Mosges R., Mullol J., Namazova Baranova L., Neffen H., Nekam K., Niedoszytko M., Odemyr M., O'Hehir R.E., Ollert M., O'Mahony L., Ohta K., Okamoto Y., Okubo K., Pajno G.B., Palomares O., Palkonen S., Panzner P., G Papadopoulos N., Park H.-S., Passalacqua G., Patella V., Pawankar R., Pham-Thi N., Plavec D., Popov T.A., Recto M., Regateiro F.S., Riggioni C., Roberts G., Rodriguez-Gonzales M., Rosario N., Rottem M., Rouadi P.W., Ryan D., Samolinski B., Sanchez-Borges✝ M., Serpa F.S., Sastre J., Scadding G.K., Shamji M.H., Schmid-Grendelmeier P., Schunemann H.J., Sheikh A., Scichilone N., Sisul J.C., Sofiev M., Sole D., Sooronbaev T., Soto-Martinez M., Soto-Quiros M., Sova M., Schwarze J., Skypala I., Suppli-Ulrik C., Taborda-Barata L., Todo-Bom A., Torres M.J., Valentin-Rostan M., Tomazic P.-V., Valero A., Toppila-Salmi S., Tsiligianni I., Untersmayr E., Urrutia-Pereira M., Valiulis A., Valovirta E., Vandenplas O., Ventura M.T., Vichyanond P., Wagenmann M., Wallace D., Walusiak-Skorupa J., Wang D.Y., Waserman S., Wong G.W.K., Yorgancioglu A., Yusuf O.M., Zernotti M., Zhang L., Zidarn M., Zuberbier T., Jutel M., HUS Inflammation Center, Department of Dermatology, Allergology and Venereology, University of Helsinki, Department of Pathology, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Philipps Universität Marburg = Philipps University of Marburg, Transilvania University of Brasov, Universität Zürich [Zürich] = University of Zurich (UZH), Humanitas University [Milan] (Hunimed), Universidad San Pablo CEU, Kuwait University, Al-Rashed Allergy Center [Kuwait City], Pantai Hospital [Kuala Lumpur], Hospital Quirónsalud Bizkaia [Bilbao], Ghent University Hospital, Karolinska Institutet [Stockholm], Karolinska University Hospital [Stockholm], Sun Yat-Sen University [Guangzhou] (SYSU), Universiti Sains Malaysia (USM), Humboldt University Of Berlin, Berlin Institute of Health (BIH), Odense University Hospital (OUH), Skane University Hospital [Lund], Fondazione Policlinico Universitario Agostino Gemelli IRCCS, National Heart and Lung Institute [London] (NHLI), Imperial College London-Royal Brompton and Harefield NHS Foundation Trust, Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma] (Unicatt), Woolcock Institute of Medical Research [Sydney], The University of Sydney, Guy's and St Thomas' Hospital [London], King‘s College London, Università degli studi di Torino = University of Turin (UNITO), University of Cartagena, Vall d'Hebron University Hospital [Barcelona], Centro Hospitalar de Lisboa Central E.P.E, NOVA Medical School - Faculdade de Ciências Médicas (NMS), Universidade Nova de Lisboa = NOVA University Lisbon (NOVA)-Universidade Nova de Lisboa = NOVA University Lisbon (NOVA), University of South Florida [Tampa] (USF), Azienda Usl Toscana centro [Firenze], Universidad Simon Bolivar (USB), David Tvildiani Medical University (DTMU), McMaster University [Hamilton, Ontario], Children's Clinical University Hospital [Riga, Latvia] (CCUH), Universidade Federal da Bahia (UFBA), Università degli Studi di Cagliari = University of Cagliari (UniCa), Epidemiology of Allergic and Respiratory Diseases Department [iPlesp] (EPAR), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Hôpital Foch [Suresnes], Sagamihara National Hospital [Kanagawa, Japan], Université Ain Shams, Vilnius University [Vilnius], CHU Clermont-Ferrand, IRCCS Ospedale Pediatrico Bambino Gesù [Roma], Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA), European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Universidade do Porto = University of Porto, Silesian Medical University, Katowice, Poland, Cerrahpasa Faculty of Medicine, Istanbul University, Erasmus University Medical Center [Rotterdam] (Erasmus MC), Universidad de Chile = University of Chile [Santiago] (UCHILE), Humanitas Clinical and Research Center [Rozzano, Milan, Italy], Medizinische Universität Wien = Medical University of Vienna, Hôtel-Dieu de France (HDF), Université Saint-Joseph de Beyrouth (USJ), Tartu University Hospital [Tartu, Estonia], Ukrainina Medical Stomatological Academy [Poltava, Ukraine], Hacettepe University = Hacettepe Üniversitesi, Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Siriraj Hospital, Mahidol University, Mahidol University [Bangkok], Nova Southeastern University (NSU), Nofer Institute of Occupational Medicine (NIOM), National University of Singapore (NUS), Yong Loo Lin School of Medicine [Singapore], The Chinese University of Hong Kong [Hong Kong], Manisa Celal Bayar University, Universidad Nacional de Villa María, Universidad Católica de Córdoba, Beijing Tongren Hospital, Herrada, Anthony, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, and UCL - (MGD) Service de pneumologie

Subjects
Pulmonary and Respiratory Medicine, precision medicine, education, Immunology, Review, Settore MED/10 - Malattie Dell'Apparato Respiratorio, immune system diseases, HDE ALER, allergic rhinitis, asthma, immunotherapy, Medicine and Health Sciences, Immunology and Allergy, [SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology, ComputingMilieux_MISCELLANEOUS, Rhinitis, RC581-607, respiratory tract diseases, 3121 General medicine, internal medicine and other clinical medicine, Immunologic diseases. Allergy, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit, [SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology, allergic rhinitis, asthma, immunotherapy, precision medicine
Abstract

Funding Information: BSreports personal fees from Allergopharma, during the conduct of the study; grants from National Health Programm, grant, personal fees from Polpharma, ASTRA, personal fees from Mylan, Adamed, patient ombudsman, national Centre for Research and Development, Polish Allergology Society. Funding Information: NGP reports personal fees from Novartis, Nutricia, HAL, MENARINI/FAES FARMA, SANOFI, MYLAN/MEDA, BIOMAY, AstraZeneca, GSK, MSD, ASIT BIOTECH, Boehringer Ingelheim, grants from Gerolymatos International SA, Capricare. Funding Information: CA reports grants from Allergopharma, grants from Idorsia, Swiss National Science Foundation, Christine Kühne‐Center for Allergy Research and Education, European Commission's Horison's 2020 Framework Programme, Cure, Novartis Research Institutes, Astra Zeneca, scibase, advisory role in Sanofi/Regeneron, grants from Glakso Smith‐Kline, advisory role in scibase. Funding Information: MJTreports grants from European Commission, SEAIC, ISCIII, personal fees from Diater laboratory, Leti laboratory, Aimmune Therapeutics. Funding Information: LK reports grants and personal fees from Allergopharma, MEDA/Mylan, LETI Pharma, Sanofi, grants from Stallergenes, Quintiles, ASIT biotech, grants from ALK Abelló, Lofarma, AstraZeneca, GSK, Inmunotk, personal fees from Allergy Therapeut., HAL Allergie, Cassella med; and Membership: AeDA, DGHNO, Deutsche Akademie für Allergologie und klinische Immunologie, HNO‐BV, GPA, EAACI. Funding Information: DPreports grants and personal fees from GlaxoSmithKline, personal fees from Menarini, Pliva, Belupo, AbbVie, Novartis, MSD, Chiesi, Revenio, personal fees and non‐financial support from Boehringer Ingelheim, non‐financial support from Philips. Funding Information: OP reports grants and personal fees from ALK‐Abelló, Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, ASIT Biotech Tools S.A., Laboratorios LETI/LETI Pharma, Anergis S.A., Glaxo Smith Kline, grants from Biomay, Circassia, Pohl‐Boskamp, Inmunotek S.L., personal fees from MEDA Pharma/MYLAN, Mobile Chamber Experts (a GA2LEN Partner), Indoor Biotechnologies, Astellas Pharma Global, EUFOREA, ROXALL Medizin, Novartis, Sanofi‐Aventis and Sanofi‐Genzyme, Med Update Europe GmbH, streamedup! GmbH, John Wiley and Sons, AS. Copyright: Copyright 2021 Elsevier B.V., All rights reserved. publishersversion published

Published
2021

14. ARIA masterclass 2018: From guidelines to real-life implementation

Author

Hellings, Peter W, Seys, Sven F, Marien, Gert, Agache, Ioana, Canonica, Walter, Gevaert, Philippe, Haahtela, Tari, Klimek, Ludger, Mullol, Joaquim, Pfaar, Oliver, Scadding, Glenis, Scadding, Guy, Valiulis, Arunas, Bousquet, Jean, Pugin, Benoit, Al-Muhandis, Nada, Allatt, Sarah, Almeyda, Robert, Armand, Patricia, Markovic, Marina Atanaskovic, Bajoriuniene, Ieva, Banik, Abhijit-Neil, Barbar-Craig, Humera, Barraclough, James, Bedfert, Cecile, Bedrock, Ana, Beel, Mieke, Parra, David Bonilla, Bradatan, Elena, Bras, Michael, Brehmer, Detlef, Brinkman, David, Cardier Suarez, Marisela, Carrasco Llatas, Marina, Chipev, Petar, Cooper, Angela, Corbett, Dennis, Cox, Caroline, Cox, Tony, Decsi, Melinda, Dantsis, Christos, Davies, Danielle, de la Hoz, Belen, Dordal Culla, Maria Teresa, Dworan-Timler, Astrid, Edlinger, Stefan, El Rakhawy, Mohamed, El-Shanawany, Tariq, Elhendi Halawa, Wassim, Fauquert, Jean-Luc, Folliard, Aoife, Frankland, Karen, Gardner, James, Gaskin, Julian, Guiddur, Tamazoust, Hanks, Kerry-Ann, Hanna, Brendan, Heinz, Benjamin, Hettige, Roland, Horisberger, Alice, Hosotte, Maxime, Howe, David, Hox, Valerie, Ifeacho, Sonna, Jain, Anurag, Jaramillo, Mario, Jimenez Morales, Juan Miguel, Kale, Savita, Kamper, Yvonne, Kansal, Gaurav, Kapustova, Lenka, Karamchandani, Dheeraj, Keh, Siew, Kerr, Ute, Khan, Maha, Kosnik, Mitja, Kolar, Matej, Koos, Beate, Kostov, Kosta, Kraxner, Helga, Kvedariene, Violeta, Lawton, Simon, Lefevre, Sebastien, Lentari, Eirini, Lindenberger, Martin, Litschel, Ralph, Lozar, Miha, Lomikovska, Marta, Luckhardt, Clemens, Lukits, Julia, Marchuk, Oksana, Marlair, Caroline, Martens, Katleen, Maria Mateo, Jose, Mc Donald, Stephen, Menaches Guardiola, Maria Isabel, Mohammad, Mohammad, Cosme, Joana Moreno, Morgans, Montio, Morris, Abigail, Mustakov, Tihomir, Nadeem, Shahid, Nagy, Attila, Nemecek, Romina, Nemeth, Barbara, Neukirch, Catherine, Odeh, Ihab, Patiar, Shalini, Pavic, Milena, Peglion, Armony, Pentland, Julie, de Corgnol, Anne Christine Perrot, Petrovicova, Otilia, Piccininni, Krizia, Piont, Valeryi, Popov, Todor, Popovics, Emese, Portejoie, Fabienne, Quirce, Santiago, Ram, Bhaskar, Ramonaite, Agne, Juratli, Abdul Razzak, Rico, Pilar, Ritterhoff, Carsten, Robertson, Alasdair, Fernandes, Rosa Rodrigues, Runge, Sonja, Ryan, Dermot, Sanchez Gutierrez, Rafael, Schatteman, Isabelle, Scheire, Sophie, Schuhmacher-Koval, Aleksandra, Scola Pliego, Esteban, Shukla, Rishi, Siau, Derrick, Siemers, Maaike, Sitkauskiene, Brigita, Slomskis, Tomas, Kosak, Tanja Soklic, Speleman, Kato, Spindler, Thomas, Straetmans, Jos, Striupaitiene, Dina, Sunk, Werner, Tadikonda, Rajendra, Tariq, Muhammad, Terporten, Barbara, Toma, Shamim, Tor, Mirabela, Tsirevelou, Paraskevi, Urban, Matthias, Urbancic, Jure, van der Putten, Lisa, Vasiliu, Vlad-Corneliu, Vesilyk, Nataliia, Vink, Anna-Sophie, Vriess-Uss, Elena, Vu, Kieuhanh, Yaremchuk, Svitlana, Yong, Patrick, Zahoor, Tosief, Zidarn, Mihaela, Ear, Nose and Throat, University Hospitals Leuven [Leuven], Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Transilvania University of Brasov, Istituto Clinico Humanitas [Milan] (IRCCS Milan), Humanitas University [Milan] (Hunimed), Ghent University Hospital, University of Helsinki, Heidelberg University, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), CIBER de Epidemiología y Salud Pública (CIBERESP), Philipps University of Marburg, Royal Brompton and Harefield NHS Foundation Trust, University College of London [London] (UCL), Vilnius University [Vilnius], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), and Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)

Subjects
IMPACT, Best practice, MEDLINE, CHILDREN, MECHANISMS, 03 medical and health sciences, 0302 clinical medicine, Belgium, RISK-FACTOR, Mobile technology, MANAGEMENT, Humans, Medicine, In real life, IMMUNOTHERAPY, 030223 otorhinolaryngology, masterclass, ALLERGIC RHINITIS SYMPTOMS, Research data, Asthma therapy, Medical education, Science & Technology, ARIA, allergic rhinitis, PRODUCTIVITY, business.industry, Change management, General Medicine, asthma, MILD, Rhinitis, Allergic, Asthma, 3. Good health, Integrated care, Multimorbidities, Integrated Care Pathways, Otorhinolaryngology, ARIA (Allergic Rhinitis and its Impact on Asthma), [SDV.IMM]Life Sciences [q-bio]/Immunology, Clinical Competence, business, Life Sciences & Biomedicine
Abstract

Over the past 20 years, ARIA (Allergic Rhinitis and its Impact on Asthma) has developed various guidelines for the treatment of allergic rhinitis (AR) and asthma multimorbidity. Over time, the ARIA initiative has evolved to ensure the highest level of bestpractices adoption in real life settings. It has evolved towards Integrated Care Pathways (ICPs) using mobile technology, and has now entered a new phase in which change management is key to provide an active and healthy life to all AR patients. With that in mind, the first ARIA masterclass was held on 12th September 2018 in Brussels, Belgium. The masterclass aimed at informing clinicians about the principles of change management, providing unbiased education on diagnosis and treatments, sharing the most recent research data on AR and multimorbidities, and creating a snowball effect to increase the adoption of best practices around the globe. This report provides an overview of the ARIA masterclass concept, summarizes the key lectures and discussions, and gives an outline of the future key development. ispartof: RHINOLOGY vol:57 issue:5 pages:392-399 ispartof: location:Netherlands status: published

Published
2019

16. Patient-centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA-EAACI approach - ARIA-EAACI Task Force Report.

Author

Bousquet J, Shamji MH, Anto JM, Schünemann HJ, Canonica GW, Jutel M, Del Giacco S, Zuberbier T, Pfaar O, Fonseca JA, Sousa-Pinto B, Klimek L, Czarlewski W, Bedbrook A, Amaral R, Ansotegui IJ, Bosnic-Anticevich S, Braido F, Chaves Loureiro C, Gemicioglu B, Haahtela T, Kulus M, Kuna P, Kupczyk M, Matricardi PM, Regateiro FS, Samolinski B, Sofiev M, Toppila-Salmi S, Valiulis A, Ventura MT, Barbara C, Bergmann KC, Bewick M, Blain H, Bonini M, Boulet LP, Bourret R, Brusselle G, Brussino L, Buhl R, Cardona V, Casale T, Cecchi L, Charpin D, Cherrez-Ojeda I, Chu DK, Cingi C, Costa EM, Cruz AA, Devillier P, Dramburg S, Fokkens WJ, Gotua M, Heffler E, Ispayeva Z, Ivancevich JC, Joos G, Kaidashev I, Kraxner H, Kvedariene V, Larenas-Linnemann DE, Laune D, Lourenço O, Louis R, Makela M, Makris M, Maurer M, Melén E, Micheli Y, Morais-Almeida M, Mullol J, Niedoszytko M, O'Hehir R, Okamoto Y, Olze H, Papadopoulos NG, Papi A, Patella V, Pétré B, Pham-Thi N, Puggioni F, Quirce S, Roche N, Rouadi PW, Sá-Sousa A, Sagara H, Sastre J, Scichilone N, Sheikh A, Sova M, Suppli Ulrik C, Taborda-Barata L, Todo-Bom A, Torres MJ, Tsiligianni I, Usmani OS, Valovirta E, Vasankari T, Vieira RJ, Wallace D, Waserman S, Zidarn M, Yorgancioglu A, Zhang L, Chivato T, and Ollert M

Subjects
Humans, Biomarkers, Patient-Centered Care, Rhinitis, Asthma diagnosis, Asthma therapy, Rhinitis, Allergic diagnosis, Rhinitis, Allergic therapy, Respiration Disorders
Abstract

Biomarkers for the diagnosis, treatment and follow-up of patients with rhinitis and/or asthma are urgently needed. Although some biologic biomarkers exist in specialist care for asthma, they cannot be largely used in primary care. There are no validated biomarkers in rhinitis or allergen immunotherapy (AIT) that can be used in clinical practice. The digital transformation of health and health care (including mHealth) places the patient at the center of the health system and is likely to optimize the practice of allergy. Allergic Rhinitis and its Impact on Asthma (ARIA) and EAACI (European Academy of Allergy and Clinical Immunology) developed a Task Force aimed at proposing patient-reported outcome measures (PROMs) as digital biomarkers that can be easily used for different purposes in rhinitis and asthma. It first defined control digital biomarkers that should make a bridge between clinical practice, randomized controlled trials, observational real-life studies and allergen challenges. Using the MASK-air app as a model, a daily electronic combined symptom-medication score for allergic diseases (CSMS) or for asthma (e-DASTHMA), combined with a monthly control questionnaire, was embedded in a strategy similar to the diabetes approach for disease control. To mimic real-life, it secondly proposed quality-of-life digital biomarkers including daily EQ-5D visual analogue scales and the bi-weekly RhinAsthma Patient Perspective (RAAP). The potential implications for the management of allergic respiratory diseases were proposed., (© 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)

Published
2023
Full Text
View/download PDF

17. Consistent trajectories of rhinitis control and treatment in 16,177 weeks: The MASK-air® longitudinal study.

Author

Sousa-Pinto B, Schünemann HJ, Sá-Sousa A, Vieira RJ, Amaral R, Anto JM, Klimek L, Czarlewski W, Mullol J, Pfaar O, Bedbrook A, Brussino L, Kvedariene V, Larenas-Linnemann DE, Okamoto Y, Ventura MT, Agache I, Ansotegui IJ, Bergmann KC, Bosnic-Anticevich S, Canonica GW, Cardona V, Carreiro-Martins P, Casale T, Cecchi L, Chivato T, Chu DK, Cingi C, Costa EM, Cruz AA, Del Giacco S, Devillier P, Eklund P, Fokkens WJ, Gemicioglu B, Haahtela T, Ivancevich JC, Ispayeva Z, Jutel M, Kuna P, Kaidashev I, Khaitov M, Kraxner H, Laune D, Lipworth B, Louis R, Makris M, Monti R, Morais-Almeida M, Mösges R, Niedoszytko M, Papadopoulos NG, Patella V, Pham-Thi N, Regateiro FS, Reitsma S, Rouadi PW, Samolinski B, Sheikh A, Sova M, Todo-Bom A, Taborda-Barata L, Toppila-Salmi S, Sastre J, Tsiligianni I, Valiulis A, Vandenplas O, Wallace D, Waserman S, Yorgancioglu A, Zidarn M, Zuberbier T, Fonseca JA, and Bousquet J

Subjects
Humans, Longitudinal Studies, Surveys and Questionnaires, Rhinitis epidemiology, Telemedicine
Abstract

Introduction: Data from mHealth apps can provide valuable information on rhinitis control and treatment patterns. However, in MASK-air®, these data have only been analyzed cross-sectionally, without considering the changes of symptoms over time. We analyzed data from MASK-air® longitudinally, clustering weeks according to reported rhinitis symptoms., Methods: We analyzed MASK-air® data, assessing the weeks for which patients had answered a rhinitis daily questionnaire on all 7 days. We firstly used k-means clustering algorithms for longitudinal data to define clusters of weeks according to the trajectories of reported daily rhinitis symptoms. Clustering was applied separately for weeks when medication was reported or not. We compared obtained clusters on symptoms and rhinitis medication patterns. We then used the latent class mixture model to assess the robustness of results., Results: We analyzed 113,239 days (16,177 complete weeks) from 2590 patients (mean age ± SD = 39.1 ± 13.7 years). The first clustering algorithm identified ten clusters among weeks with medication use: seven with low variability in rhinitis control during the week and three with highly-variable control. Clusters with poorly-controlled rhinitis displayed a higher frequency of rhinitis co-medication, a more frequent change of medication schemes and more pronounced seasonal patterns. Six clusters were identified in weeks when no rhinitis medication was used, displaying similar control patterns. The second clustering method provided similar results. Moreover, patients displayed consistent levels of rhinitis control, reporting several weeks with similar levels of control., Conclusions: We identified 16 patterns of weekly rhinitis control. Co-medication and medication change schemes were common in uncontrolled weeks, reinforcing the hypothesis that patients treat themselves according to their symptoms., (© 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)

Published
2023
Full Text
View/download PDF

18. Digitally-enabled, patient-centred care in rhinitis and asthma multimorbidity: The ARIA-MASK-air ® approach.

Author

Bousquet J, Anto JM, Sousa-Pinto B, Czarlewski W, Bedbrook A, Haahtela T, Klimek L, Pfaar O, Kuna P, Kupczyk M, Regateiro FS, Samolinski B, Valiulis A, Yorgancioglu A, Arnavielhe S, Basagaña X, Bergmann KC, Bosnic-Anticevich S, Brussino L, Canonica GW, Cardona V, Cecchi L, Chaves-Loureiro C, Costa E, Cruz AA, Gemicioglu B, Fokkens WJ, Ivancevich JC, Kraxner H, Kvedariene V, Larenas-Linnemann DE, Laune D, Louis R, Makris M, Maurer M, Melén E, Micheli Y, Morais-Almeida M, Mullol J, Niedoszytko M, Okamoto Y, Papadopoulos NG, Patella V, Pham-Thi N, Rouadi PW, Sastre J, Scichilone N, Sheikh A, Sofiev M, Taborda-Barata L, Toppila-Salmi S, Tsiligianni I, Valovirta E, Ventura MT, Vieira RJ, Zidarn M, Amaral R, Ansotegui IJ, Bédard A, Benveniste S, Bewick M, Bindslev-Jensen C, Blain H, Bonini M, Bourret R, Braido F, Carreiro-Martins P, Charpin D, Cherrez-Ojeda I, Chivato T, Chu DK, Cingi C, Del Giacco S, de Blay F, Devillier P, De Vries G, Doulaptsi M, Doyen V, Dray G, Fontaine JF, Gomez RM, Hagemann J, Heffler E, Hofmann M, Jassem E, Jutel M, Keil T, Kritikos V, Kull I, Kulus M, Lourenço O, Mathieu-Dupas E, Menditto E, Mösges R, Murray R, Nadif R, Neffen H, Nicola S, O'Hehir R, Olze H, Palamarchuk Y, Pépin JL, Pétré B, Picard R, Pitsios C, Puggioni F, Quirce S, Raciborski F, Reitsma S, Roche N, Rodriguez-Gonzalez M, Romantowski J, Sá-Sousa A, Serpa FS, Savouré M, Shamji MH, Sova M, Sperl A, Stellato C, Todo-Bom A, Tomazic PV, Vandenplas O, Van Eerd M, Vasankari T, Viart F, Waserman S, Fonseca JA, and Zuberbier T

Abstract

MASK-air ® , a validated mHealth app (Medical Device regulation Class IIa) has enabled large observational implementation studies in over 58,000 people with allergic rhinitis and/or asthma. It can help to address unmet patient needs in rhinitis and asthma care. MASK-air ® is a Good Practice of DG Santé on digitally-enabled, patient-centred care. It is also a candidate Good Practice of OECD (Organisation for Economic Co-operation and Development). MASK-air ® data has enabled novel phenotype discovery and characterisation, as well as novel insights into the management of allergic rhinitis. MASK-air ® data show that most rhinitis patients (i) are not adherent and do not follow guidelines, (ii) use as-needed treatment, (iii) do not take medication when they are well, (iv) increase their treatment based on symptoms and (v) do not use the recommended treatment. The data also show that control (symptoms, work productivity, educational performance) is not always improved by medications. A combined symptom-medication score (ARIA-EAACI-CSMS) has been validated for clinical practice and trials. The implications of the novel MASK-air ® results should lead to change management in rhinitis and asthma., (© 2023 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.)

Published
2023
Full Text
View/download PDF

19. Comparison of rhinitis treatments using MASK-air® data and considering the minimal important difference.

Author

Sousa-Pinto B, Schünemann HJ, Sá-Sousa A, Vieira RJ, Amaral R, Anto JM, Klimek L, Czarlewski W, Mullol J, Pfaar O, Bedbrook A, Brussino L, Kvedariene V, Larenas-Linnemann D, Okamoto Y, Ventura MT, Agache I, Ansotegui IJ, Bergmann KC, Bosnic-Anticevich S, Brozek J, Canonica GW, Cardona V, Carreiro-Martins P, Casale T, Cecchi L, Chivato T, Chu DK, Cingi C, Costa EM, Cruz AA, Del Giacco S, Devillier P, Eklund P, Fokkens WJ, Gemicioglu B, Haahtela T, Ivancevich JC, Ispayeva Z, Jutel M, Kuna P, Kaidashev I, Khaitov M, Kraxner H, Laune D, Lipworth B, Louis R, Makris M, Monti R, Morais-Almeida M, Mösges R, Niedoszytko M, Papadopoulos NG, Patella V, Pham-Thi N, Regateiro FS, Reitsma S, Rouadi PW, Samolinski B, Sheikh A, Sova M, Todo-Bom A, Taborda-Barata L, Toppila-Salmi S, Sastre J, Tsiligianni I, Valiulis A, Vandenplas O, Wallace D, Waserman S, Yorgancioglu A, Zidarn M, Zuberbier T, Fonseca JA, and Bousquet J

Subjects
Adrenal Cortex Hormones therapeutic use, Desensitization, Immunologic, Fluticasone therapeutic use, Humans, Rhinitis drug therapy, Rhinitis, Allergic therapy
Abstract

Background: Different treatments exist for allergic rhinitis (AR), including pharmacotherapy and allergen immunotherapy (AIT), but they have not been compared using direct patient data (i.e., "real-world data"). We aimed to compare AR pharmacological treatments on (i) daily symptoms, (ii) frequency of use in co-medication, (iii) visual analogue scales (VASs) on allergy symptom control considering the minimal important difference (MID) and (iv) the effect of AIT., Methods: We assessed the MASK-air® app data (May 2015-December 2020) by users self-reporting AR (16-90 years). We compared eight AR medication schemes on reported VAS of allergy symptoms, clustering data by the patient and controlling for confounding factors. We compared (i) allergy symptoms between patients with and without AIT and (ii) different drug classes used in co-medication., Results: We analysed 269,837 days from 10,860 users. Most days (52.7%) involved medication use. Median VAS levels were significantly higher in co-medication than in monotherapy (including the fixed combination azelastine-fluticasone) schemes. In adjusted models, azelastine-fluticasone was associated with lower average VAS global allergy symptoms than all other medication schemes, while the contrary was observed for oral corticosteroids. AIT was associated with a decrease in allergy symptoms in some medication schemes. A difference larger than the MID compared to no treatment was observed for oral steroids. Azelastine-fluticasone was the drug class with the lowest chance of being used in co-medication (adjusted OR = 0.75; 95% CI = 0.71-0.80)., Conclusion: Median VAS levels were higher in co-medication than in monotherapy. Patients with more severe symptoms report a higher treatment, which is currently not reflected in guidelines., (© 2022 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)

Published
2022
Full Text
View/download PDF

20. Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK-air ® real-world data.

Author

Sousa-Pinto B, Sá-Sousa A, Vieira RJ, Amaral R, Klimek L, Czarlewski W, Antó JM, Pfaar O, Bedbrook A, Kvedariene V, Ventura MT, Ansotegui IJ, Bergmann KC, Brussino L, Canonica GW, Cardona V, Carreiro-Martins P, Casale T, Cecchi L, Chivato T, Chu DK, Cingi C, Costa EM, Cruz AA, De Feo G, Devillier P, Fokkens WJ, Gaga M, Gemicioğlu B, Haahtela T, Ivancevich JC, Ispayeva Z, Jutel M, Kuna P, Kaidashev I, Kraxner H, Larenas-Linnemann DE, Laune D, Lipworth B, Louis R, Makris M, Monti R, Morais-Almeida M, Mösges R, Mullol J, Odemyr M, Okamoto Y, Papadopoulos NG, Patella V, Pham-Thi N, Regateiro FS, Reitsma S, Rouadi PW, Samolinski B, Sova M, Todo-Bom A, Taborda-Barata L, Tomazic PV, Toppila-Salmi S, Sastre J, Tsiligianni I, Valiulis A, Vandenplas O, Wallace D, Waserman S, Yorgancioglu A, Zidarn M, Zuberbier T, Fonseca JA, and Bousquet J

Subjects
Europe epidemiology, Habits, Histamine Antagonists therapeutic use, Humans, Rhinitis drug therapy, Rhinitis, Allergic drug therapy, Rhinitis, Allergic epidemiology
Abstract

Background: Co-medication is common among patients with allergic rhinitis (AR), but its dimension and patterns are unknown. This is particularly relevant since AR is understood differently across European countries, as reflected by rhinitis-related search patterns in Google Trends. This study aims to assess AR co-medication and its regional patterns in Europe, using real-world data., Methods: We analysed 2015-2020 MASK-air ® European data. We compared days under no medication, monotherapy and co-medication using the visual analogue scale (VAS) levels for overall allergic symptoms ('VAS Global Symptoms') and impact of AR on work. We assessed the monthly use of different medication schemes, performing separate analyses by region (defined geographically or by Google Trends patterns). We estimated the average number of different drugs reported per patient within 1 year., Results: We analysed 222,024 days (13,122 users), including 63,887 days (28.8%) under monotherapy and 38,315 (17.3%) under co-medication. The median 'VAS Global Symptoms' was 7 for no medication days, 14 for monotherapy and 21 for co-medication (p < .001). Medication use peaked during the spring, with similar patterns across different European regions (defined geographically or by Google Trends). Oral H 1 -antihistamines were the most common medication in single and co-medication. Each patient reported using an annual average of 2.7 drugs, with 80% reporting two or more., Conclusions: Allergic rhinitis medication patterns are similar across European regions. One third of treatment days involved co-medication. These findings suggest that patients treat themselves according to their symptoms (irrespective of how they understand AR) and that co-medication use is driven by symptom severity., (© 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)

Published
2022
Full Text
View/download PDF

21. Allergen immunotherapy in MASK-air users in real-life: Results of a Bayesian mixed-effects model.

Author

Sousa-Pinto B, Azevedo LF, Sá-Sousa A, Vieira RJ, Amaral R, Klimek L, Czarlewski W, Anto JM, Bedbrook A, Kvedariene V, Ventura MT, Ansotegui IJ, Bergmann KC, Brussino L, Canonica GW, Cardona V, Carreiro-Martins P, Casale T, Cecchi L, Chivato T, Chu DK, Cingi C, Costa EM, Cruz AA, De Feo G, Devillier P, Fokkens WJ, Gaga M, Gemicioğlu B, Haahtela T, Ivancevich JC, Ispayeva Z, Jutel M, Kuna P, Kaidashev I, Kraxner H, Larenas-Linnemann DE, Laune D, Lipworth B, Louis R, Makris M, Monti R, Morais-Almeida M, Mösges R, Mullol J, Odemyr M, Okamoto Y, Papadopoulos NG, Patella V, Pham-Thi N, Regateiro FS, Reitsma S, Rouadi PW, Samolinski B, Sova M, Todo-Bom A, Taborda-Barata L, Tomazic PV, Toppila-Salmi S, Sastre J, Tsiligianni I, Valiulis A, Wallace D, Waserman S, Yorgancioglu A, Zidarn M, Zuberbier T, Fonseca JA, Bousquet J, and Pfaar O

Abstract

Background: Evidence regarding the effectiveness of allergen immunotherapy (AIT) on allergic rhinitis has been provided mostly by randomised controlled trials, with little data from real-life studies., Objective: To compare the reported control of allergic rhinitis symptoms in three groups of users of the MASK-air ® app: those receiving sublingual AIT (SLIT), those receiving subcutaneous AIT (SCIT), and those receiving no AIT., Methods: We assessed the MASK-air ® data of European users with self-reported grass pollen allergy, comparing the data reported by patients receiving SLIT, SCIT and no AIT. Outcome variables included the daily impact of allergy symptoms globally and on work (measured by visual analogue scales-VASs), and a combined symptom-medication score (CSMS). We applied Bayesian mixed-effects models, with clustering by patient, country and pollen season., Results: We analysed a total of 42,756 days from 1,093 grass allergy patients, including 18,479 days of users under AIT. Compared to no AIT, SCIT was associated with similar VAS levels and CSMS. Compared to no AIT, SLIT-tablet was associated with lower values of VAS global allergy symptoms (average difference = 7.5 units out of 100; 95% credible interval [95%CrI] = -12.1;-2.8), lower VAS Work (average difference = 5.0; 95%CrI = -8.5;-1.5), and a lower CSMS (average difference = 3.7; 95%CrI = -9.3;2.2). When compared to SCIT, SLIT-tablet was associated with lower VAS global allergy symptoms (average difference = 10.2; 95%CrI = -17.2;-2.8), lower VAS Work (average difference = 7.8; 95%CrI = -15.1;0.2), and a lower CSMS (average difference = 9.3; 95%CrI = -18.5;0.2)., Conclusion: In patients with grass pollen allergy, SLIT-tablet, when compared to no AIT and to SCIT, is associated with lower reported symptom severity. Future longitudinal studies following internationally-harmonised standards for performing and reporting real-world data in AIT are needed to better understand its 'real-world' effectiveness., (© 2022 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.)

Published
2022
Full Text
View/download PDF

22. Management of anaphylaxis due to COVID-19 vaccines in the elderly.

Author

Bousquet J, Agache I, Blain H, Jutel M, Ventura MT, Worm M, Del Giacco S, Benetos A, Bilo BM, Czarlewski W, Abdul Latiff AH, Al-Ahmad M, Angier E, Annesi-Maesano I, Atanaskovic-Markovic M, Bachert C, Barbaud A, Bedbrook A, Bennoor KS, Berghea EC, Bindslev-Jensen C, Bonini S, Bosnic-Anticevich S, Brockow K, Brussino L, Camargos P, Canonica GW, Cardona V, Carreiro-Martins P, Carriazo A, Casale T, Caubet JC, Cecchi L, Cherubini A, Christoff G, Chu DK, Cruz AA, Dokic D, El-Gamal Y, Ebisawa M, Eberlein B, Farrell J, Fernandez-Rivas M, Fokkens WJ, Fonseca JA, Gao Y, Gavazzi G, Gawlik R, Gelincik A, Gemicioğlu B, Gotua M, Guérin O, Haahtela T, Hoffmann-Sommergruber K, Hoffmann HJ, Hofmann M, Hrubisko M, Illario M, Irani C, Ispayeva Z, Ivancevich JC, Julge K, Kaidashev I, Khaitov M, Knol E, Kraxner H, Kuna P, Kvedariene V, Lauerma A, Le LTT, Le Moing V, Levin M, Louis R, Lourenco O, Mahler V, Martin FC, Matucci A, Milenkovic B, Miot S, Montella E, Morais-Almeida M, Mortz CG, Mullol J, Namazova-Baranova L, Neffen H, Nekam K, Niedoszytko M, Odemyr M, O'Hehir RE, Okamoto Y, Ollert M, Palomares O, Papadopoulos NG, Panzner P, Passalacqua G, Patella V, Petrovic M, Pfaar O, Pham-Thi N, Plavec D, Popov TA, Recto MT, Regateiro FS, Reynes J, Roller-Winsberger RE, Rolland Y, Romano A, Rondon C, Rottem M, Rouadi PW, Salles N, Samolinski B, Santos AF, S Sarquis F, Sastre J, M G A Schols J, Scichilone N, Sediva A, Shamji MH, Sheikh A, Skypala I, Smolinska S, Sokolowska M, Sousa-Pinto B, Sova M, Stelmach R, Sturm G, Suppli Ulrik C, Todo-Bom AM, Toppila-Salmi S, Tsiligianni I, Torres M, Untersmayr E, Urrutia Pereira M, Valiulis A, Vitte J, Vultaggio A, Wallace D, Walusiak-Skorupa J, Wang DY, Waserman S, Yorgancioglu A, Yusuf OM, Zernotti M, Zidarn M, Chivato T, Akdis CA, Zuberbier T, and Klimek L

Subjects
Aged, COVID-19 Vaccines, Epinephrine, Humans, Male, SARS-CoV-2, Anaphylaxis etiology, Anaphylaxis prevention & control, COVID-19
Abstract

Older adults, especially men and/or those with diabetes, hypertension, and/or obesity, are prone to severe COVID-19. In some countries, older adults, particularly those residing in nursing homes, have been prioritized to receive COVID-19 vaccines due to high risk of death. In very rare instances, the COVID-19 vaccines can induce anaphylaxis, and the management of anaphylaxis in older people should be considered carefully. An ARIA-EAACI-EuGMS (Allergic Rhinitis and its Impact on Asthma, European Academy of Allergy and Clinical Immunology, and European Geriatric Medicine Society) Working Group has proposed some recommendations for older adults receiving the COVID-19 vaccines. Anaphylaxis to COVID-19 vaccines is extremely rare (from 1 per 100,000 to 5 per million injections). Symptoms are similar in younger and older adults but they tend to be more severe in the older patients. Adrenaline is the mainstay treatment and should be readily available. A flowchart is proposed to manage anaphylaxis in the older patients., (© 2021 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.)

Published
2021
Full Text
View/download PDF

23. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy.

Author

Bousquet J, Pfaar O, Agache I, Bedbrook A, Akdis CA, Canonica GW, Chivato T, Al-Ahmad M, Abdul Latiff AH, Ansotegui IJ, Bachert C, Baharuddin A, Bergmann KC, Bindslev-Jensen C, Bjermer L, Bonini M, Bosnic-Anticevich S, Bosse I, Brough HA, Brussino L, Calderon MA, Caraballo L, Cardona V, Carreiro-Martins P, Casale T, Cecchi L, Cepeda Sarabia AM, Chkhartishvili E, Chu DK, Cirule I, Cruz AA, Czarlewski W, Del Giacco S, Demoly P, Devillier P, Dokic D, Durham SL, Ebisawa M, El-Gamal Y, Emuzyte R, Gamkrelidze A, Fauquert JL, Fiocchi A, Fokkens WJ, Fonseca JA, Fontaine JF, Gawlik R, Gelincik A, Gemicioglu B, Gereda JE, Gerth van Wijk R, Gomez RM, Gotua M, Grisle I, Guzmán MA, Haahtela T, Halken S, Heffler E, Hoffmann-Sommergruber K, Hossny E, Hrubiško M, Irani C, Ivancevich JC, Ispayeva Z, Julge K, Kaidashev I, Kalayci O, Khaitov M, Klimek L, Knol E, Kowalski ML, Kraxner H, Kull I, Kuna P, Kvedariene V, Kritikos V, Lauerma A, Lau S, Laune D, Levin M, Larenas-Linnemann DE, Lodrup Carlsen KC, Lombardi C, Lourenço OM, Mahboub B, Malling HJ, Manning P, Marshall GD, Melén E, Meltzer EO, Miculinic N, Milenkovic B, Moin M, Montefort S, Morais-Almeida M, Mortz CG, Mösges R, Mullol J, Namazova Baranova L, Neffen H, Nekam K, Niedoszytko M, Odemyr M, O'Hehir RE, Ollert M, O'Mahony L, Ohta K, Okamoto Y, Okubo K, Pajno GB, Palomares O, Palkonen S, Panzner P, G Papadopoulos N, Park HS, Passalacqua G, Patella V, Pawankar R, Pham-Thi N, Plavec D, Popov TA, Recto M, Regateiro FS, Riggioni C, Roberts G, Rodriguez-Gonzales M, Rosario N, Rottem M, Rouadi PW, Ryan D, Samolinski B, Sanchez-Borges M, Serpa FS, Sastre J, Scadding GK, Shamji MH, Schmid-Grendelmeier P, Schünemann HJ, Sheikh A, Scichilone N, Sisul JC, Sofiev M, Solé D, Sooronbaev T, Soto-Martinez M, Soto-Quiros M, Sova M, Schwarze J, Skypala I, Suppli-Ulrik C, Taborda-Barata L, Todo-Bom A, Torres MJ, Valentin-Rostan M, Tomazic PV, Valero A, Toppila-Salmi S, Tsiligianni I, Untersmayr E, Urrutia-Pereira M, Valiulis A, Valovirta E, Vandenplas O, Ventura MT, Vichyanond P, Wagenmann M, Wallace D, Walusiak-Skorupa J, Wang Y, Waserman S, Wong GW, Yorgancioglu A, Yusuf OM, Zernotti M, Zhang L, Zidarn M, Zuberbier T, and Jutel M

Abstract

Competing Interests: IAgache is an Associate Editor Allergy and CTA. CA reports grants from Allergopharma, grants from Idorsia, Swiss National Science Foundation, Christine Kühne‐Center for Allergy Research and Education, European Commission's Horison's 2020 Framework Programme, Cure, Novartis Research Institutes, Astra Zeneca, scibase, advisory role in Sanofi/Regeneron, grants from Glakso Smith‐Kline, advisory role in scibase. IA reports personal fees from Hikma, Roxall, Astra Zeneca, Menarini, UCB, Faes Farma, Sanofi, Mundipharma, Bial, Amgen, Stallergenes. SBA reports grants from TEVA, personal fees from TEVA, AstraZeneca, Boehringer Ingelheim, GSK, Sanofi, Mylan. VC reports personal fees from ALK, Allergy Therapeutics, LETI, Thermofisher, Merck, Astrazeneca, GSK. TC reports grants and personal fees from Stallergenes. PD reports personal fees from ALK‐Abello, Stallergenes‐Greer, Astra Zeneca, GlaxoSmithKline, Mylan, Sanofi. SD reports personal fees and non‐financial support from ALK Abello, personal fees from Adiga, Biomay, Allergopharma, Anergis, Allergy Therapeutics. TH reports personal fees from GSK, Mundipharma, Orion Pharma. SH reports other from ALK‐Abelló, other from ALK‐Abelló. EH reports personal fees from Sanofi, Novartis, GSK, AstraZeneca, Circassia, Nestlè Purina. JCI reports personal fees from Faes Farma, Laboratorios Casasco Argentina, Abbott de Ecuador, EuroFarma Argentina. MJ reports personal fees from ALK‐Abello, Allergopharma, Stallergenes, Anergis, Allergy Therapeutics, Circassia, Leti, Biomay, HAL, during the conduct of the study; personal fees from Astra‐Zeneka, GSK, Novartis, Teva, Vectura, UCB, Takeda, Roche, Janssen, Medimmune, Chiesi,. LK reports grants and personal fees from Allergopharma, MEDA/Mylan, LETI Pharma, Sanofi, grants from Stallergenes, Quintiles, ASIT biotech, grants from ALK Abelló, Lofarma, AstraZeneca, GSK, Inmunotk, personal fees from Allergy Therapeut., HAL Allergie, Cassella med; and Membership: AeDA, DGHNO, Deutsche Akademie für Allergologie und klinische Immunologie, HNO‐BV, GPA, EAACI. PK reports personal fees from Adamed, Berlin Chemie Menarini, Boehringer Ingelheim, AstraZeneca, Lekam, Novartis, Polpharma, GSK, Polpharma, Sanofi, teva. VK reports other from GSK, non‐financial support from Mylan, AstraZeneca, Dimuna, Norameda. SL reports personal fees from DBV, Sanofi Aventis, Allergopharma, ALK, Nutricia, Bencard. EM reports personal fees from Sanofi, Novartis, AstraZeneca and Chiesi. JM reports personal fees and other from SANOFI‐GENZYME & REGENERON, NOVARTIS, ALLAKOS, MITSUBISHI‐TANABE, MENARINI, UCB, ASTRAZENECA, GSK, MSD, grants and personal fees from MYLAN‐MEDA Pharma, URIACH Group. MO reports personal fees from Hycor Diagnostics, Thermo Fisher Phadia. YO reports personal fees from Torii Pharmaceutical Co., Ltd., Shionogi Pharmaceutical Co.,Ltd. OP received research grants from Inmunotek S.L., Novartis and MINECO and has received fees for giving scientific lectures or participation in Advisory Boards from: Allergy Therapeutics, Amgen, AstraZeneca, Diater, GlaxoSmithKline, S.A, Inmunotek S.L, Novartis, Sanofi‐Genzyme and Stallergenes. NGP reports personal fees from Novartis, Nutricia, HAL, MENARINI/FAES FARMA, SANOFI, MYLAN/MEDA, BIOMAY, AstraZeneca, GSK, MSD, ASIT BIOTECH, Boehringer Ingelheim, grants from Gerolymatos International SA, Capricare. OP reports grants and personal fees from ALK‐Abelló, Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, ASIT Biotech Tools S.A., Laboratorios LETI/LETI Pharma, Anergis S.A., Glaxo Smith Kline, grants from Biomay, Circassia, Pohl‐Boskamp, Inmunotek S.L., personal fees from MEDA Pharma/MYLAN, Mobile Chamber Experts (a GA2LEN Partner), Indoor Biotechnologies, Astellas Pharma Global, EUFOREA, ROXALL Medizin, Novartis, Sanofi‐Aventis and Sanofi‐Genzyme, Med Update Europe GmbH, streamedup! GmbH, John Wiley and Sons, AS. DPreports grants and personal fees from GlaxoSmithKline, personal fees from Menarini, Pliva, Belupo, AbbVie, Novartis, MSD, Chiesi, Revenio, personal fees and non‐financial support from Boehringer Ingelheim, non‐financial support from Philips. MR is on the Advisory board‐ A. Menarini ‐ Speaker ‐ Astra Zeneca, Novartis, Sanofi, Mylan. FSRreports speaker and advisory fees from AstraZeneca, Novartis, Sanofi, GSK, Teva and Lusomedicamenta. GR reports payment to his Institution from Allergo Pharma. BSreports personal fees from Allergopharma, during the conduct of the study; grants from National Health Programm, grant, personal fees from Polpharma, ASTRA, personal fees from Mylan, Adamed, patient ombudsman, national Centre for Research and Development, Polish Allergology Society. JS reports grants and personal fees from Sanofi, personal fees from GSK, Novartis, Astra Zeneca, Mundipharma, Faes Farma. GS reports personal fees from ALK, and leds on the BSACI Rhinitis Guidelines and lead for EUFOREA on Allergic Rhinitis. PSG reports personal fees from Allergopharma, ALK, grants from Bencard, grants and personal fees from Stallergenes. JS reports personal fees from Mylan, F2F events. ATB reports grants and personal fees from Teva, AstraZeneca, GSK Sanofi, Mundipharma, personal fees from Bial, Novartis. MJTreports grants from European Commission, SEAIC, ISCIII, personal fees from Diater laboratory, Leti laboratory, Aimmune Therapeutics. MW reports personal fees from ALK‐Abello, Allergopharma, AstraZeneca, Bencard, Genzyme, GlaxoSmithKline, HAL Allergy, LETI, Meda Pharma, Novartis, Sanofi, Stallergenes, Teva. DW reports other from Optinose, ALK, Sanofi; past Co‐Chair of the Joint Task Force on Practice Parameters of the AAAAI and ACAAI. Second author of a recently published practice parameter on Rhinitis. MW reports other from Aralez (Medexus), Pediapharm, Pfizer, Astra Zeneca, GSK, Alk. MZ reports personal fees from Takeda. TZ reports and Organizational affiliations: Commitee member: WHO‐Initiative “Allergic Rhinitis and Its Impact on Asthma” (ARIA). Member of the Board: German Society for Allergy and Clinical Immunology (DGAKI). Head: European Centre for Allergy Research Foundation (ECARF). Secretary General: Global Allergy and Asthma European Network (GA2LEN). Member: Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organization (WAO). FIGURE 1Countries with Pocket Guide membersFIGURE 2Proposed Flow of Precision Medicine approach in allergic diseases. *examples of exceptions: Thunderstorm‐induced asthma, patient with moderate rhinitis and severe asthma during pollen seasonFIGURE 3Treatment algorithm using visual analogue scale (VAS) for adolescents and adults AIT, allergen immunotherapy; VAS, visual analogue scale.FIGURE 4Algorithm for AIT in asthma

Published
2021
Full Text
View/download PDF

24. ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020).

Author

Bousquet J, Jutel M, Akdis CA, Klimek L, Pfaar O, Nadeau KC, Eiwegger T, Bedbrook A, Ansotegui IJ, Anto JM, Bachert C, Bateman ED, Bennoor KS, Berghea EC, Bergmann KC, Blain H, Bonini M, Bosnic-Anticevich S, Boulet LP, Brussino L, Buhl R, Camargos P, Canonica GW, Cardona V, Casale T, Chinthrajah S, Akdis M, Chivato T, Christoff G, Cruz AA, Czarlewski W, Del Giacco S, Du H, El-Gamal Y, Fokkens WJ, Fonseca JA, Gao Y, Gaga M, Gemicioglu B, Gotua M, Haahtela T, Halpin D, Hamelmann E, Hoffmann-Sommergruber K, Humbert M, Ilina N, Ivancevich JC, Joos G, Khaitov M, Kirenga B, Knol EF, Ko FW, Koskinen S, Kowalski ML, Kraxner H, Kudlay D, Kuna P, Kupczyk M, Kvedariene V, Abdul Latiff AH, Le LT, Levin M, Larenas-Linnemann D, Louis R, Masjedi MR, Melén E, Mihaltan F, Milenkovic B, Mohammad Y, Morais-Almeida M, Mullol J, Namazova L, Neffen H, Nunes E, O'Byrne P, O'Hehir R, O'Mahony L, Ohta K, Okamoto Y, Onorato GL, Panzner P, Papadopoulos NG, Passalacqua G, Patella V, Pawankar R, Pham-Thi N, Pigearias B, Popov TA, Puggioni F, Regateiro FS, Rolla G, Rottem M, Samolinski B, Sastre J, Schwarze J, Sheikh A, Scichilone N, Soto-Quiros M, Soto-Martinez M, Sova M, Nicola S, Stelmach R, Suppli-Ulrik C, Taborda-Barata L, To T, Tomazic PV, Toppila-Salmi S, Tsiligianni I, Usmani O, Valiulis A, Ventura MT, Viegi G, Vontetsianos T, Wang Y, Williams S, Wong GWK, Yorgancioglu A, Zernotti M, Zidarn M, Zuberbier T, and Agache I

Subjects
Angiotensin-Converting Enzyme 2 physiology, Asthma drug therapy, Humans, Asthma complications, COVID-19 etiology, SARS-CoV-2
Published
2021
Full Text
View/download PDF

25. Potential Interplay between Nrf2, TRPA1, and TRPV1 in Nutrients for the Control of COVID-19.

Author

Bousquet J, Czarlewski W, Zuberbier T, Mullol J, Blain H, Cristol JP, De La Torre R, Pizarro Lozano N, Le Moing V, Bedbrook A, Agache I, Akdis CA, Canonica GW, Cruz AA, Fiocchi A, Fonseca JA, Fonseca S, Gemicioğlu B, Haahtela T, Iaccarino G, Ivancevich JC, Jutel M, Klimek L, Kraxner H, Kuna P, Larenas-Linnemann DE, Martineau A, Melén E, Okamoto Y, Papadopoulos NG, Pfaar O, Regateiro FS, Reynes J, Rolland Y, Rouadi PW, Samolinski B, Sheikh A, Toppila-Salmi S, Valiulis A, Choi HJ, Kim HJ, and Anto JM

Subjects
Antioxidants metabolism, Biomarkers metabolism, Brassica, COVID-19 complications, COVID-19 diagnosis, COVID-19 Testing, Desensitization, Immunologic methods, Down-Regulation, Humans, Oxidative Stress immunology, SARS-CoV-2 pathogenicity, Severity of Illness Index, Up-Regulation, COVID-19 diet therapy, COVID-19 immunology, NF-E2-Related Factor 2 immunology, Nutrients immunology, SARS-CoV-2 immunology, TRPA1 Cation Channel immunology, TRPV Cation Channels immunology
Abstract

In this article, we propose that differences in COVID-19 morbidity may be associated with transient receptor potential ankyrin 1 (TRPA1) and/or transient receptor potential vanilloid 1 (TRPV1) activation as well as desensitization. TRPA1 and TRPV1 induce inflammation and play a key role in the physiology of almost all organs. They may augment sensory or vagal nerve discharges to evoke pain and several symptoms of COVID-19, including cough, nasal obstruction, vomiting, diarrhea, and, at least partly, sudden and severe loss of smell and taste. TRPA1 can be activated by reactive oxygen species and may therefore be up-regulated in COVID-19. TRPA1 and TRPV1 channels can be activated by pungent compounds including many nuclear factor (erythroid-derived 2) (Nrf2)-interacting foods leading to channel desensitization. Interactions between Nrf2-associated nutrients and TRPA1/TRPV1 may be partly responsible for the severity of some of the COVID-19 symptoms. The regulation by Nrf2 of TRPA1/TRPV1 is still unclear, but suggested from very limited clinical evidence. In COVID-19, it is proposed that rapid desensitization of TRAP1/TRPV1 by some ingredients in foods could reduce symptom severity and provide new therapeutic strategies., (© 2021 S. Karger AG, Basel.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results